Overview

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Status:
Terminated

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Facet Biotech

Collaborator:

Biogen

Treatments:

Antibodies, Monoclonal
Volociximab